Nadine McGrath

Neurizon Therapeutics, Arovella Therapeutics and Singular Health Group are among ASX health companies reporting quarterly results this week.

ASX closes 0.52% lower on Tuesday as BHP agrees to pay $110 million to settle an Australian class action over deadly Samarco dam collapse. 

Starpharma surges 81% after signing a collaboration and licensing deal with Genentech, a member of the Big Pharma Roche Group.

Regenerative medicine is a fast-growing field harnessing the body’s natural healing ability and has become a focus for several ASX biotechs.

Backed by government and industry partners, Micro-X is pushing its cold-cathode X-ray tech toward commercial readiness.

Aroa's (ASX:ARX) multichannel sales strategy of its soft-tissue repair products is driving a long-term, scaleable pathway to growth.

Recce is developing a new class of antibiotics to tackle drug-resistant superbugs almost a century after the development of penicillin.

Innovative ASX healthcare companies are working to reduce costly and ongoing challenge of post-surgery complications.  

Securing US FDA approval is a milestone for medical device companies but is only half the story with successful adoption also challenging.

Several ASX healthcare companies are tackling neurodegenerative diseases where effective treatments remain limited.